首页> 外国专利> MODIFIED RELEASE 1-(3-HYDROXY-ADAMANT-1-YLAMINO)-ACETYL-PYRROLIDINE-2(S)-CARBONITRILE FORMULATION

MODIFIED RELEASE 1-(3-HYDROXY-ADAMANT-1-YLAMINO)-ACETYL-PYRROLIDINE-2(S)-CARBONITRILE FORMULATION

机译:修饰的发布1-[((3-羟基-ADAMANT-1-YLAMINO)-乙炔基]-吡咯烷-2(S)-碳腈配制

摘要

To provide a pharmaceutical tablet formulation, which can be compressed, preferably compressed directly, into a tablet having a suitable hardness/fragility, acceptable disintegration time, low moisture sensitivity, better stability, a pattern of acceptable solution, and a better pharmacokinetic profile in treated patients.SOLUTION: A pharmaceutical tablet formulation comprises, per unit dosage form e.g. per tablet, the following ingredients: (a) a compound as an active ingredient or a pharmaceutically acceptable salt thereof, the compound having formula (a): (wherein R is substituted adamantyl and n is an integer from 0 to 3); (b) a hydroxypropyl methylcellulose with an apparent viscosity of 80,000 cP to 120,000 cP (nominal value 100,000 cP) when present in a 1% solution; (c) a microcrystalline cellulose; and (d) a magnesium stearate.SELECTED DRAWING: None
机译:为了提供可以压制,优选直接压制成片剂的药物片剂,该片剂具有合适的硬度/脆弱性,可接受的崩解时间,低湿度敏感性,更好的稳定性,可接受的溶液形式和在治疗中更好的药代动力学特征解决方案:药物片剂包含每单位剂型,例如每片含有以下成分:(a)作为活性成分的化合物或其药学上可接受的盐,具有式(a)的化合物:(其中R为取代的金刚烷基,n为0至3的整数); (b)当在1%的溶液中存在时,表观粘度为80,000 cP至120,000 cP(标称值100,000 cP)的羟丙基甲基纤维素; (c)微晶纤维素; (d)硬脂酸镁。

著录项

  • 公开/公告号JP2020055816A

    专利类型

  • 公开/公告日2020-04-09

    原文格式PDF

  • 申请/专利权人 NOVARTIS AG;

    申请/专利号JP20190205708

  • 申请日2019-11-13

  • 分类号A61K31/40;A61K47/38;A61K47/12;A61K9/22;A61P3/10;A61P3/06;A61P9/10;A61P31;A61P1/02;A61P27/16;A61P9;A61P43;

  • 国家 JP

  • 入库时间 2022-08-21 11:36:17

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号